As of 2024-12-12, the Relative Valuation of Lipigon Pharmaceuticals AB (LPGO.ST) is (2.80) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 0.19 SEK, the upside of Lipigon Pharmaceuticals AB based on Relative Valuation is -1554.2%.
The range of the Relative Valuation is (2.50) - (2.98) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 18.6x | 15.5x |
| Forward P/E multiples | 15.6x - 23.4x | 19.5x |
| Fair Price | (2.50) - (2.98) | (2.80) |
| Upside | -1396.3% - -1645.6% | -1554.2% |
| Date | P/E |
| 2024-12-09 | -1.25 |
| 2024-12-06 | -1.06 |
| 2024-12-05 | -1.06 |
| 2024-12-04 | -1.12 |
| 2024-12-03 | -1.06 |
| 2024-12-02 | -1.06 |
| 2024-11-29 | -1.09 |
| 2024-11-28 | -1.03 |
| 2024-11-27 | -1.05 |
| 2024-11-26 | -1.09 |
| 2024-11-25 | -1.07 |
| 2024-11-22 | -1.03 |
| 2024-11-21 | -1.06 |
| 2024-11-20 | -0.81 |
| 2024-11-19 | -0.86 |
| 2024-11-18 | -0.85 |
| 2024-11-15 | -0.78 |
| 2024-11-14 | -0.81 |
| 2024-11-13 | -0.83 |
| 2024-11-12 | -0.87 |
| 2024-11-11 | -0.95 |
| 2024-11-08 | -0.97 |
| 2024-11-07 | -1.04 |
| 2024-11-06 | -1.05 |
| 2024-11-05 | -1.01 |
| 2024-11-04 | -1.06 |
| 2024-11-01 | -1.06 |
| 2024-10-31 | -1.07 |
| 2024-10-30 | -1.13 |
| 2024-10-29 | -1.18 |
| 2024-10-28 | -1.14 |
| 2024-10-25 | -1.20 |
| 2024-10-24 | -1.17 |
| 2024-10-23 | -1.23 |
| 2024-10-22 | -1.16 |
| 2024-10-21 | -1.17 |
| 2024-10-18 | -1.15 |
| 2024-10-17 | -1.15 |
| 2024-10-16 | -1.08 |
| 2024-10-15 | -1.21 |
| 2024-10-14 | -1.30 |
| 2024-10-11 | -1.57 |
| 2024-10-10 | -1.62 |
| 2024-10-09 | -1.69 |
| 2024-10-08 | -1.81 |
| 2024-10-07 | -1.50 |
| 2024-10-04 | -1.54 |
| 2024-10-03 | -1.59 |
| 2024-10-02 | -1.68 |
| 2024-10-01 | -1.56 |